Bidirectional links between Alzheimer's disease and Niemann-Pick type C disease

Neurobiology of Disease

Volumn 72, Issue Part A, 2014, Pages 37-47

  Malnar, Martina ^a   Hecimovic, Silva ^a   Mattsson, Niklas ^b,c,d   Zetterberg, Henrik ^b,e  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid ; Cholesterol; Lipids; Niemann Pick type C disease; NPC1; Tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; LIPID; TAU PROTEIN; APOLIPOPROTEIN E; CARRIER PROTEIN; MEMBRANE PROTEIN; NPC1 PROTEIN, HUMAN; NPC1 PROTEIN, MOUSE; PROTEIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; APOE EPSILON 4 GENE; CHOLESTEROL METABOLISM; CLINICAL FEATURE; DISEASE ASSOCIATION; ENDOCYTOSIS; GENE; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; MOLECULAR INTERACTION; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NIEMANN PICK DISEASE; NPC1 GENE; NPC2 GENE; PROTEIN METABOLISM; REVIEW; RISK FACTOR; ANIMAL; BRAIN; GENETICS; METABOLISM; MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEINS E; BRAIN; CARRIER PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; NIEMANN-PICK DISEASE, TYPE C; PROTEINS;

EID: 84909579125     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.05.033     Document Type: Review

References (122)

1. Andersen O.M., Reiche J., Schmidt V., Gotthardt M., Spoelgen R., Behlke J., et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(38):13461-13466.
2. Andreasson U., Portelius E., Andersson M.E., Blennow K., Zetterberg H. Aspects of beta-amyloid as a biomarker for Alzheimer's disease. Biomark. Med 2007, 1(1):59-78.
3. Aqul A., Liu B., Ramirez C.M., Pieper A.A., Estill S.J., Burns D.K., et al. Unesterified cholesterol accumulation in late endosomes/lysosomes causes neurodegeneration and is prevented by driving cholesterol export from this compartment. J. Neurosci. 2011, 31(25):9404-9413.
4. Armstrong A., Mattsson N., Appelqvist H., Janefjord C., Sandin L., Agholme L., et al. Lysosomal network proteins as potential novel CSF biomarkers for Alzheimer's disease. NeuroMolecular Med. 2014, 16(1):150-160.
5. Auer I.A., Schmidt M.L., Lee V.M., Curry B., Suzuki K., Shin R.W., et al. Paired helical filament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer's disease. Acta Neuropathol. 1995, 90(6):547-551.
6. Barrett P.J., Song Y., Van Horn W.D., Hustedt E.J., Schafer J.M., Hadziselimovic A., et al. The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 2012, 336(6085):1168-1171.
7. Blennow K., Zetterberg H., Rinne J.O., Salloway S., Wei J., Black R., et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch. Neurol. 2012, 69(8):1002-1010.
8. Borbon I.A., Erickson R.P. Interactions of Npc1 and amyloid accumulation/deposition in the APP/PS1 mouse model of Alzheimer's. J. Appl. Genet. 2011, 52(2):213-218.
9. Braak H., Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol. 2011, 121(2):171-181.
10. Braak H., Braak E., Bohl J., Lang W. Alzheimer's disease: amyloid plaques in the cerebellum. J. Neurol. Sci. 1989, 93(2-3):277-287.
11. Brady R.O., Filling-Katz M.R., Barton N.W., Pentchev P.G. Niemann-Pick disease types C and D. Neurol. Clin. 1989, 7(1):75-88.
12. Bu B., Klunemann H., Suzuki K., Li J., Bird T., Jin L.-W., et al. Niemann-Pick disease type C yields possible clue for why cerebellar neurons do not form neurofibrillary tangles. Neurobiol. Dis. 2002, 11(2):285-297.
13. Bu B., Li J., Davies P., Vincent I. Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J. Neurosci. 2002, 22(15):6515-6525.
14. Burns M.P., Rebeck G.W. Intracellular cholesterol homeostasis and amyloid precursor protein processing. Biochim. Biophys. Acta BBA Mol. Cell Biol. Lipids 2010, 1801(8):853-859.
15. Burns M., Gaynor K., Olm V., Mercken M., LaFrancois J., Wang L., et al. Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. J. Neurosci. 2003, 23(13):5645-5649.
16. Carey R.M., Balcz B.A., Lopez-Coviella I., Slack B.E. Inhibition of dynamin-dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid β protein. BMC Cell Biol. 2005, 6(1):30.
17. Carstea E.D., Morris J.A., Coleman K.G., Loftus S.K., Zhang D., Cummings C., et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 1997, 277(5323):228-231.
18. Cataldo A.M., Peterhoff C.M., Troncoso J.C., Gomez-Isla T., Hyman B.T., Nixon R.A. Endocytic pathway abnormalities precede amyloid β deposition in sporadic Alzheimer's disease and Down syndrome. Am. J. Pathol. 2000, 157(1):277-286.
19. Cataldo A.M., Petanceska S., Terio N.B., Peterhoff C.M., Durham R., Mercken M., et al. Aβ localization in abnormal endosomes: association with earliest Aβ elevations in AD and Down syndrome. Neurobiol. Aging 2004, 25(10):1263-1272.
20. Choi H.Y., Karten B., Chan T., Vance J.E., Greer W.L., Heidenreich R.A., et al. Impaired ABCA1-dependent lipid efflux and hypoalphalipoproteinemia in human Niemann-Pick type C disease. J. Biol. Chem. 2003, 278(35):32569-32577.
21. Cirrito J.R., Kang J.-E., Lee J., Stewart F.R., Verges D.K., Silverio L.M., et al. Endocytosis is required for synaptic activity-dependent release of amyloid-β in vivo. Neuron 2008, 58(1):42-51.
22. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261(5123):921-923.
23. Dietschy J.M., Turley S.D. Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 2004, 45(8):1375-1397.
24. Distl R., Meske V., Ohm T.G. Tangle-bearing neurons contain more free cholesterol than adjacent tangle-free neurons. Acta Neuropathol. 2001, 101(6):547-554.
25. Ehehalt R., Keller P., Haass C., Thiele C., Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 2003, 160(1):113-123.
26. Erickson R.P., Larson-Thomé K., Weberg L., Szybinska A., Mossakowska M., Styczynska M., et al. Variation in NPC1, the gene encoding Niemann-Pick C1, a protein involved in intracellular cholesterol transport, is associated with Alzheimer disease and/or aging in the Polish population. Neurosci. Lett. 2008, 447(2-3):153-157.
27. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(10):5856-5861.
28. Feldman H.H., Doody R.S., Kivipelto M., Sparks D.L., Waters D.D., Jones R.W., et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010, 74(12):956-964.
29. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366(9503):2112-2117.
30. Foley P. Lipids in Alzheimer's disease: a century-old story. Biochim. Biophys. Acta BBA Mol. Cell Biol. Lipids 2010, 1801(8):750-753.
31. Fu R., Yanjanin N.M., Elrick M.J., Ware C., Lieberman A.P., Porter F.D. Apolipoprotein E genotype and neurological disease onset in Niemann-Pick disease, type C1. Am. J. Med. Genet. A 2012, 158A(11):2775-2780.
32. German D.C., Quintero E.M., Liang C.-L., Ng B., Punia S., Xie C., et al. Selective neurodegeneration, without neurofibrillary tangles, in a mouse model of Niemann-Pick C disease. J. Comp. Neurol. 2001, 433(3):415-425.
33. German D.C., Liang C.-L., Song T., Yazdani U., Xie C., Dietschy J.M. Neurodegeneration in the Niemann-Pick C mouse: glial involvement. Neuroscience 2002, 109(3):437-450.
34. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64(9):1553-1562.
35. Ginsberg S.D., Alldred M.J., Counts S.E., Cataldo A.M., Neve R.L., Jiang Y., et al. Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression. Biol. Psychiatry 2010, 68(10):885-893.
36. Grbovic O.M., Mathews P.M., Jiang Y., Schmidt S.D., Dinakar R., Summers-Terio N.B., et al. Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production. J. Biol. Chem. 2003, 278(33):31261-31268.
37. Hamilton R.L. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000, 10(3):378-384.
38. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256(5054):184-185.
39. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297(5580):353-356.
40. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41(10):1088-1093.
41. Hayden E.Y., Teplow D.B. Amyloid β-protein oligomers and Alzheimer's disease. Alzheimers Res. Ther. 2013, 5(6):60.
42. Heverin M., Bogdanovic N., Lütjohann D., Bayer T., Pikuleva I., Bretillon L., et al. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J. Lipid Res. 2004, 45(1):186-193.
43. Hoglund K., Thelen K.M., Syversen S., Sjogren M., von Bergmann K., Wallin A., et al. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2005, 19(5-6):256-265.
44. Holtzman D.M., Herz J., Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect Med. 2012, 2(3):a006312. (Mar).
45. Infante R.E., Wang M.L., Radhakrishnan A., Kwon H.J., Brown M.S., Goldstein J.L. NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(40):15287-15292.
46. Jiang Y., Mullaney K.A., Peterhoff C.M., Che S., Schmidt S.D., Boyer-Boiteau A., et al. Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(4):1630-1635.
47. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet 2000, 356(9242):1627-1631.
48. Jin L.-W., Shie F.-S., Maezawa I., Vincent I., Bird T. Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am. J. Pathol. 2004, 164(3):975-985.
49. Jones L., Holmans P.A., Hamshere M.L., Harold D., Moskvina V., Ivanov D., et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS ONE 2010, 5(11):e13950.
50. Kågedal K., Kim W.S., Appelqvist H., Chan S., Cheng D., Agholme L., et al. Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer's disease. Biochim. Biophys. Acta 2010, 1801(8):831-838.
51. Kalvodova L., Kahya N., Schwille P., Ehehalt R., Verkade P., Drechsel D., et al. Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J. Biol. Chem. 2005, 280(44):36815-36823.
52. Kobayashi T., Beuchat M.H., Lindsay M., Frias S., Palmiter R.D., Sakuraba H., et al. Late endosomal membranes rich in lysobisphosphatidic acid regulate cholesterol transport. Nat. Cell Biol. 1999, 1(2):113-118.
53. Kodam A., Maulik M., Peake K., Amritraj A., Vetrivel K.S., Thinakaran G., et al. Altered levels and distribution of APP and its processing enzymes in Niemann-Pick type C1-deficient mouse brains. Glia 2010, 58(11):1267-1281.
54. Koo E.H., Squazzo S.L. Evidence that production and release of amyloid β-protein involves the endocytic pathway. J. Biol. Chem. 1994, 269(26):17386-17389.
55. Kosicek M., Malnar M., Goate A., Hecimovic S. Cholesterol accumulation in Niemann Pick type C (NPC) model cells causes a shift in APP localization to lipid rafts. Biochem. Biophys. Res. Commun. 2010, 393(3):404-409.
56. LaFerla F.M., Green K.N., Oddo S. Intracellular amyloid-β in Alzheimer's disease. Nat. Rev. Neurosci. 2007, 8(7):499-509.
57. Lambert J.-C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009, 41(10):1094-1099.
58. Lambert J.-C., Ibrahim-Verbaas C.A., Harold D., Naj A.C., Sims R., Bellenguez C., et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet. 2013, 45(12):1452-1458.
59. Lazar A.N., Bich C., Panchal M., Desbenoit N., Petit V.W., Touboul D., et al. Time-of-flight secondary ion mass spectrometry (TOF-SIMS) imaging reveals cholesterol overload in the cerebral cortex of Alzheimer disease patients. Acta Neuropathol. 2013, 125(1):133-144.
60. Lee S.J., Liyanage U., Bickel P.E., Xia W., Lansbury P.T., Kosik K.S. A detergent-insoluble membrane compartment contains A beta in vivo. Nat. Med. 1998, 4(6):730-734.
61. Lippa C.F., Fujiwara H., Mann D.M., Giasson B., Baba M., Schmidt M.L., et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am. J. Pathol. 1998, 153(5):1365-1370.
62. Liu C.-C., Liu C.-C., Kanekiyo T., Xu H., Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 2013, 9(2):106-118.
63. Lloyd-Evans E., Platt F.M. Lipids on trial: the search for the offending metabolite in Niemann-Pick type C disease. Traffic 2010, 11(4):419-428.
64. Loftus S.K., Morris J.A., Carstea E.D., Gu J.Z., Cummings C., Brown A., et al. Murine model of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene. Science 1997, 277(5323):232-235.
65. Loftus S.K., Erickson R.P., Walkley S.U., Bryant M.A., Incao A., Heidenreich R.A., et al. Rescue of neurodegeneration in Niemann-Pick C mice by a prion-promoter-driven Npc1 cDNA transgene. Hum. Mol. Genet. 2002, 11(24):3107-3114.
66. Love S., Bridges L.R., Case C.P. Neurofibrillary tangles in Niemann-Pick disease type C. Brain J. Neurol. 1995, 118(Pt 1):119-129.
67. Lowenthal A.C., Cummings J.F., Wenger D.A., Thrall M.A., Wood P.A., de Lahunta A. Feline sphingolipidosis resembling Niemann-Pick disease type C. Acta Neuropathol. 1990, 81(2):189-197.
68. Malnar M., Kosicek M., Mitterreiter S., Omerbasic D., Lichtenthaler S.F., Goate A., et al. Niemann-Pick type C cells show cholesterol dependent decrease of APP expression at the cell surface and its increased processing through the beta-secretase pathway. Biochim. Biophys. Acta 2010, 1802(7-8):682-691.
69. Malnar M., Kosicek M., Lisica A., Posavec M., Krolo A., Njavro J., et al. Cholesterol-depletion corrects APP and BACE1 misstrafficking in NPC1-deficient cells. Biochim. Biophys. Acta 2012, 1822(8):1270-1283.
70. Marquer C., Devauges V., Cossec J.-C., Liot G., Lécart S., Saudou F., et al. Local cholesterol increase triggers amyloid precursor protein-Bace1 clustering in lipid rafts and rapid endocytosis. FASEB J. 2011, 25(4):1295-1305.
71. Mattsson N., Zetterberg H., Bianconi S., Yanjanin N.M., Fu R., Mansson J.-E., et al. Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. Neurology 2011, 76(4):366-372.
72. Mattsson N., Olsson M., Gustavsson M.K., Kosicek M., Malnar M., Månsson J.-E., et al. Amyloid-β metabolism in Niemann-Pick C disease models and patients. Metab. Brain Dis. 2012, 27(4):573-585.
73. Mattsson N., Zetterberg H., Bianconi S., Yanjanin N.M., Fu R., Månsson J.-E., et al. Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker tau in Niemann-Pick type C. JIMD Rep. 2012, 3:45-52.
74. Maulik M., Ghoshal B., Kim J., Wang Y., Yang J., Westaway D., et al. Mutant human APP exacerbates pathology in a mouse model of NPC and its reversal by a β-cyclodextrin. Hum. Mol. Genet. 2012, 21(22):4857-4875.
75. Millard E.E., Srivastava K., Traub L.M., Schaffer J.E., Ory D.S. Niemann-Pick type C1 (NPC1) overexpression alters cellular cholesterol homeostasis. J. Biol. Chem. 2000, 275(49):38445-38451.
76. Morris M.D., Bhuvaneswaran C., Shio H., Fowler S. Lysosome lipid storage disorder in NCTR-BALB/c mice. I. Description of the disease and genetics. Am. J. Pathol. 1982, 108(2):140-149.
77. Naureckiene S., Sleat D.E., Lackland H., Fensom A., Vanier M.T., Wattiaux R., et al. Identification of HE1 as the second gene of Niemann-Pick C disease. Science 2000, 290(5500):2298-2301.
78. Neve R.L., Boyce F.M., McPhie D.L., Greenan J., Oster-Granite M.L. Transgenic mice expressing APP-C100 in the brain. Neurobiol. Aging 1996, 17(2):191-203.
79. Nunes A., Pressey S.N.R., Cooper J.D., Soriano S. Loss of amyloid precursor protein in a mouse model of Niemann-Pick type C disease exacerbates its phenotype and disrupts tau homeostasis. Neurobiol. Dis. 2011, 42(3):349-359.
80. Nuutinen T., Suuronen T., Kauppinen A., Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Res. Rev. 2009, 61(2):89-104.
81. Okamura N., Kiuchi S., Tamba M., Kashima T., Hiramoto S., Baba T., et al. A porcine homolog of the major secretory protein of human epididymis, HE1, specifically binds cholesterol. Biochim. Biophys. Acta 1999, 1438(3):377-387.
82. Pacheco C.D., Elrick M.J., Lieberman A.P. Tau deletion exacerbates the phenotype of Niemann-Pick type C mice and implicates autophagy in pathogenesis. Hum. Mol. Genet. 2009, 18(5):956-965.
83. Panchal M., Loeper J., Cossec J.-C., Perruchini C., Lazar A., Pompon D., et al. Enrichment of cholesterol in microdissected Alzheimer's disease senile plaques as assessed by mass spectrometry. J. Lipid Res. 2010, 51(3):598-605.
84. Pappolla M.A., Bryant-Thomas T.K., Herbert D., Pacheco J., Fabra Garcia M., Manjon M., et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 2003, 61(2):199-205.
85. Patterson M.C., Hendriksz C.J., Walterfang M., Sedel F., Vanier M.T., Wijburg F., et al. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol. Genet. Metab. 2012, 106(3):330-344.
86. Pentchev P.G., Gal A.E., Boothe A.D., Fouks J., Omodeo-Sale F., Brady R.O. A lysosomal storage disorder in mice characterized by the accumulation of several sphingolipids. Birth Defects Orig. Artic. Ser. 1980, 16(1):225-230.
87. Pentchev P.G., Comly M.E., Kruth H.S., Vanier M.T., Wenger D.A., Patel S., et al. A defect in cholesterol esterification in Niemann-Pick disease (type C) patients. Proc. Natl. Acad. Sci. 1985, 82(23):8247-8251.
88. Pentchev P.G., Comly M.E., Kruth H.S., Tokoro T., Butler J., Sokol J., et al. Group C Niemann-Pick disease: faulty regulation of low-density lipoprotein uptake and cholesterol storage in cultured fibroblasts. FASEB J. 1987, 1(1):40-45.
89. Pierrot N., Tyteca D., D'auria L., Dewachter I., Gailly P., Hendrickx A., et al. Amyloid precursor protein controls cholesterol turnover needed for neuronal activity. EMBO Mol. Med. 2013, 5(4):608-625.
90. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P., Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993, 342(8873):697-699.
91. Rebeck G.W., Reiter J.S., Strickland D.K., Hyman B.T. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993, 11(4):575-580.
92. Reed B., Villeneuve S., Mack W., Decarli C., Chui H.C., Jagust W. Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol. 2014, 71(2):195-200.
93. Riddell D.R., Christie G., Hussain I., Dingwall C. Compartmentalization of beta-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. Curr. Biol. 2001, 11(16):1288-1293.
94. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316(5825):750-754.
95. Rodríguez-Rodríguez E., Vázquez-Higuera J.L., Sánchez-Juan P., Mateo I., Pozueta A., Martínez-García A., et al. Epistasis between intracellular cholesterol trafficking-related genes (NPC1 and ABCA1) and Alzheimer's disease risk. J. Alzheimers Dis. 2010, 21(2):619-625.
96. Runz H., Rietdorf J., Tomic I., de Bernard M., Beyreuther K., Pepperkok R., et al. Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J. Neurosci. 2002, 22(5):1679-1689.
97. Saito Y., Suzuki K., Nanba E., Yamamoto T., Ohno K., Murayama S. Niemann-Pick type C disease: accelerated neurofibrillary tangle formation and amyloid β deposition associated with apolipoprotein E ε4 homozygosity. Ann. Neurol. 2002, 52(3):351-355.
98. Saito Y., Suzuki K., Hulette C.M., Murayama S. Aberrant phosphorylation of alpha-synuclein in human Niemann-Pick type C1 disease. J. Neuropathol. Exp. Neurol. 2004, 63(4):323-328.
99. Sano M., Bell K.L., Galasko D., Galvin J.E., Thomas R.G., van Dyck C.H., et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011, 77(6):556-563.
100. Shahim P., Darin N., Andreasson U., Blennow K., Jennions E., Lundgren J., et al. Cerebrospinal fluid brain injury biomarkers in children: a multicenter study. Pediatr. Neurol. 2013, 49(1):31-39. (e2).
101. Small S.A., Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008, 60(4):534-542.
102. Somers K.L., Wenger D.A., Royals M.A., Carstea E.D., Connally H.E., Kelly T., et al. Complementation studies in human and feline Niemann-Pick type C disease. Mol. Genet. Metab. 1999, 66(2):117-121.
103. Suzuki K., Parker C.C., Pentchev P.G., Katz D., Ghetti B., D'Agostino A.N., et al. Neurofibrillary tangles in Niemann-Pick disease type C. Acta Neuropathol. 1995, 89(3):227-238.
104. Talbot C., Lendon C., Craddock N., Shears S., Morris J.C., Goate A. Protection against Alzheimer's disease with apoE epsilon 2. Lancet 1994, 343(8910):1432-1433.
105. Tamboli I.Y., Prager K., Thal D.R., Thelen K.M., Dewachter I., Pietrzik C.U., et al. Loss of gamma-secretase function impairs endocytosis of lipoprotein particles and membrane cholesterol homeostasis. J. Neurosci. 2008, 28(46):12097-12106.
106. Tong X.-K., Nicolakakis N., Fernandes P., Ongali B., Brouillette J., Quirion R., et al. Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. Neurobiol. Dis. 2009, 35(3):406-414.
107. Vanier M.T. Niemann-Pick disease type C. Orphanet J. Rare Dis. 2010, 5:16.
108. Vanier M.T., Millat G. Niemann-Pick disease type C. Clin. Genet. 2003, 64(4):269-281.
109. Wang K., Li M., Bucan M. Pathway-based approaches for analysis of genomewide association studies. Am. J. Hum. Genet. 2007, 81(6):1278-1283.
110. Weber P., Wagner M., Schneckenburger H. Microfluorometry of cell membrane dynamics. Cytometry A 2006, 69(3):185-188.
111. Winkler E., Hobson S., Fukumori A., Dümpelfeld B., Luebbers T., Baumann K., et al. Purification, pharmacological modulation, and biochemical characterization of interactors of endogenous human gamma-secretase. Biochemistry (Mosc) 2009, 48(6):1183-1197.
112. Wollmer M.A., Sleegers K., Ingelsson M., Zekanowski C., Brouwers N., Maruszak A., et al. Association study of cholesterol-related genes in Alzheimer's disease. Neurogenetics 2007, 8(3):179-188.
113. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 2000, 57(10):1439-1443.
114. Xie C., Burns D.K., Turley S.D., Dietschy J.M. Cholesterol is sequestered in the brains of mice with Niemann-Pick type C disease but turnover is increased. J. Neuropathol. Exp. Neurol. 2000, 59(12):1106-1117.
115. Xiong H., Callaghan D., Jones A., Walker D.G., Lue L.-F., Beach T.G., et al. Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol. Dis. 2008, 29(3):422-437.
116. Yamada M., Huang Z., Dalkara T., Endres M., Laufs U., Waeber C., et al. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J. Cereb. Blood Flow Metab. 2000, 20(4):709-717.
117. Yamazaki T., Chang T.-Y., Haass C., Ihara Y. Accumulation and aggregation of amyloid beta-protein in late endosomes of Niemann-Pick type C cells. J. Biol. Chem. 2001, 276(6):4454-4460.
118. Yang J., Benyamin B., McEvoy B.P., Gordon S., Henders A.K., Nyholt D.R., et al. Common SNPs explain a large proportion of the heritability for human height. Nat. Genet. 2010, 42(7):565-569.
119. Yao J., Ho D., Calingasan N.Y., Pipalia N.H., Lin M.T., Beal M.F. Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease. J. Exp. Med. 2012, 209(13):2501-2513.
120. Yu W., Ko M., Yanagisawa K., Michikawa M. Neurodegeneration in heterozygous Niemann-Pick type C1 (NPC1) mouse: implication of heterozygous NPC1 mutations being a risk for tauopathy. J. Biol. Chem. 2005, 280(29):27296-27302.
121. Zervas M., Dobrenis K., Walkley S.U. Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations. J. Neuropathol. Exp. Neurol. 2001, 60(1):49-64.
122. Zhang M., Li J., Chakrabarty P., Bu B., Vincent I. Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice. Am. J. Pathol. 2004, 165(3):843-853.